Is CJC-1295 Legal in Brazil? (2026 Research Status)

A single subcutaneous injection of CJC-1295 elevated growth hormone levels by up to tenfold for nearly a week in healthy adults — a finding that captured the attention of researchers worldwide when it was first published Teichman et al., 2006. That kind of sustained biological activity is precisely what makes this synthetic peptide compound scientifically interesting. It’s also what makes its regulatory status complicated.

If you’re a researcher, clinician, or science enthusiast based in Brazil — or working with Brazilian institutions — you’ve likely encountered conflicting information about whether CJC-1295 is legal to purchase, possess, or use in research settings. The answer isn’t a simple yes or no. It depends on context, intent, and how Brazil’s regulatory agencies classify the compound at any given moment.

This guide breaks down what we know about CJC-1295’s legal standing in Brazil as of 2026, grounded in regulatory frameworks rather than speculation.

What Is CJC-1295?

Before diving into legality, a brief primer is useful. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It’s designed to stimulate the pituitary gland to release growth hormone (GH) in a pulsatile manner that research suggests may mimic natural physiological patterns Ionescu et al., 2006.

The compound exists in two primary forms:

• CJC-1295 without DAC (Drug Affinity Complex): Sometimes referred to as modified GRF (1-29), this version has a shorter half-life and produces more transient GH pulses.
• CJC-1295 with DAC: This version binds to albumin in the bloodstream, extending its half-life significantly — which is the variant studied in the landmark Teichman trial.

Research to date has been limited to small clinical studies and preclinical work. No major regulatory agency has approved CJC-1295 as a pharmaceutical product for human therapeutic use. That distinction matters enormously when evaluating its legal status anywhere, including Brazil.

Brazil’s Regulatory Landscape for Peptides

Brazil regulates pharmaceuticals, biologics, and research chemicals through ANVISA (Agência Nacional de Vigilância Sanitária), the national health surveillance agency. ANVISA’s classification system determines whether a substance is treated as a controlled pharmaceutical, a research-only chemical, or something else entirely.

Several layers of regulation are relevant:

1. ANVISA’s Pharmaceutical Classification

ANVISA maintains lists of substances classified as controlled medications under RDC No. 660/2022 and related resolutions. Substances on these lists require prescriptions, special licensing, and are subject to import restrictions. As of 2026, CJC-1295 does not appear on ANVISA’s primary controlled substance schedules in the same way that anabolic steroids or certain hormones do.

However, this doesn’t automatically make it “legal” in an unrestricted sense. Brazil’s regulatory framework includes catch-all provisions that allow ANVISA to regulate novel bioactive compounds even if they aren’t explicitly named on a list.

2. The Controlled Substance Framework

Brazil’s Portaria SVS/MS No. 344/1998 (and its subsequent amendments) governs lists of controlled substances organized into categories — from narcotics and psychotropics to anabolic agents and other regulated chemicals. Growth hormone secretagogues and GHRH analogs have historically fallen into a gray zone. Some peptide compounds that stimulate GH release have been explicitly listed; others have not.

The critical question is whether CJC-1295 is classified as an anabolic agent or a hormone analog subject to the same restrictions as exogenous growth hormone. Research indicates that regulatory agencies in multiple countries have struggled with this classification question, and Brazil is no exception Alba et al., 2006.

3. Research Use vs. Human Use

Brazilian law distinguishes between substances used in legitimate scientific research and those intended for human consumption or therapeutic application. Universities and accredited research institutions can often obtain compounds for preclinical or clinical research through specific licensing pathways, even when those same compounds would be restricted for general sale.

This distinction is crucial. A compound that is perfectly legal to use in an approved research protocol at a Brazilian university may be illegal to sell as a “research chemical” to individuals online.

So, Is CJC-1295 Legal in Brazil in 2026?

Here’s the honest, nuanced answer: it depends on what you mean by “legal” and what you intend to do with it.

For Researchers in Accredited Institutions

If you’re conducting research at a Brazilian university or accredited laboratory, CJC-1295 can typically be obtained through proper institutional channels. This requires:

• An approved research protocol (often reviewed by an ethics committee, or CEP/CEUA in Brazil)
• Proper import documentation if the compound is sourced internationally
• Compliance with ANVISA’s requirements for research-grade chemicals

In this context, CJC-1295 occupies a space similar to other unapproved research compounds — accessible for science, but tightly regulated in terms of sourcing and handling.

For Individual Purchase

This is where things get murky. CJC-1295 is not an approved pharmaceutical product in Brazil (or anywhere else). It cannot be legally marketed as a medication, supplement, or health product. Selling it for human consumption would likely violate multiple ANVISA regulations.

Purchasing it from international suppliers for personal use raises additional concerns around customs enforcement, import regulations, and the legal ambiguity of possessing an unclassified bioactive compound. Brazilian customs authorities have broad discretion to seize substances that aren’t clearly documented as approved imports.

For Compounding Pharmacies

Brazilian compounding pharmacies (farmácias de manipulação) operate under specific ANVISA guidelines and state-level pharmacy boards. Some compounding pharmacies have historically prepared peptide formulations, but the regulatory environment has tightened considerably. Whether a compounding pharmacy can legally prepare CJC-1295 depends on current ANVISA guidance and the specific state’s pharmacy regulations — and this landscape continues to evolve.

How Does Brazil Compare to Other Countries?

Brazil’s approach is broadly consistent with how many countries handle CJC-1295:

• United States: CJC-1295 is not FDA-approved. It exists in a gray market for “research chemicals,” and the FDA has issued warning letters to companies selling it for human use.
• European Union: Not approved as a medicine. Regulatory treatment varies by member state.
• Australia: The Therapeutic Goods Administration (TGA) has classified certain GHRH analogs as prescription-only, though enforcement varies.

For a broader look at peptide legality across jurisdictions, see our guide on whether peptides are legal again in 2026.

What the Research Actually Shows

It’s worth stepping back and examining what the science says, independent of legal questions. The clinical evidence for CJC-1295 remains limited:

• Teichman et al. (2006) demonstrated that CJC-1295 with DAC produced sustained increases in GH and IGF-1 levels in healthy adults, with effects lasting up to six days post-injection. The study involved only 11 subjects.
• Ionescu et al. (2006) showed that continuous stimulation with CJC-1295 maintained pulsatile GH secretion, suggesting the compound preserved physiological release patterns rather than producing a constant, non-pulsatile elevation.
• Alba et al. (2006) found that once-daily CJC-1295 administration normalized GH secretion in adults with growth hormone deficiency, though the study was small and preliminary.

These studies are promising but preliminary. No large-scale Phase III trials have been conducted. No regulatory agency has reviewed CJC-1295 for approval as a therapeutic agent. The gap between early-stage research findings and established medical use is substantial.

Practical Considerations for Brazilian Researchers

If you’re working with CJC-1295 in a Brazilian research context, here are some practical points to keep in mind:

1. Document everything. Maintain clear records of your research protocol, sourcing, and institutional approvals.
2. Work with your institution’s regulatory office. Brazilian universities typically have offices that handle import permits and ANVISA compliance for research materials.
3. Stay current. Regulatory classifications can change. ANVISA periodically updates its lists and guidance documents.
4. Source carefully. If you’re looking into where to buy CJC-1295 for research purposes, ensure suppliers provide certificates of analysis and operate within legal frameworks.

Frequently Asked Questions

Is CJC-1295 a controlled substance in Brazil?

CJC-1295 is not explicitly listed on Brazil’s primary controlled substance schedules as of 2026. However, it may be subject to regulation under ANVISA’s broader authority over unapproved pharmaceutical compounds. Its legal status depends heavily on the context of possession and use.

Can I import CJC-1295 into Brazil for personal use?

Importing CJC-1295 for personal use carries significant legal risk. Brazilian customs and ANVISA regulate the importation of pharmaceutical compounds, and an unapproved peptide may be seized. Legitimate research imports require institutional documentation and proper licensing.

Is CJC-1295 approved by ANVISA?

No. As of 2026, CJC-1295 has not been approved by ANVISA as a pharmaceutical product for human use. It remains classified as a research compound without therapeutic approval.

Can Brazilian compounding pharmacies prepare CJC-1295?

This depends on current ANVISA guidance and state-level pharmacy regulations. The regulatory environment for compounded peptides in Brazil has become more restrictive in recent years, and pharmacies must comply with specific requirements. Researchers should consult directly with regulatory authorities for current guidance.

Where can I learn more about CJC-1295’s research profile?

Our CJC-1295 compound page provides a comprehensive overview of the available research, including study summaries, mechanism of action, and current evidence quality.

This article is for educational and informational purposes only. It does not constitute legal advice, medical advice, or a recommendation to purchase or use any compound. Always consult qualified legal and medical professionals for guidance specific to your situation and jurisdiction.